ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
16.31
-0.65 (-3.83%)
At close: Oct 31, 2024, 4:00 PM
18.10
+1.79 (10.97%)
After-hours: Oct 31, 2024, 7:59 PM EDT
ADMA Biologics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADMA Biologics stock have an average target of 15.5, with a low estimate of 10 and a high estimate of 20. The average target predicts a decrease of -4.97% from the current stock price of 16.31.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADMA Biologics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +10.36% | Oct 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $20 | Buy | Reiterates | $20 | +22.62% | Sep 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $18 | Strong Buy | Maintains | $10 → $18 | +10.36% | Aug 12, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $15 → $20 | Buy | Maintains | $15 → $20 | +22.62% | Aug 9, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $10 → $15 | Buy | Maintains | $10 → $15 | -8.03% | Jul 9, 2024 |
Financial Forecast
Revenue This Year
413.87M
from 258.22M
Increased by 60.28%
Revenue Next Year
470.44M
from 413.87M
Increased by 13.67%
EPS This Year
0.50
from -0.13
EPS Next Year
0.68
from 0.50
Increased by 36.06%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 430.8M | 490.6M | 579.3M | ||
| Avg | 413.9M | 470.4M | 554.6M | ||
| Low | 393.9M | 441.2M | 525.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 66.8% | 18.5% | 23.1% | ||
| Avg | 60.3% | 13.7% | 17.9% | ||
| Low | 52.5% | 6.6% | 11.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.51 | 0.77 | 0.78 | ||
| Avg | 0.50 | 0.68 | 0.73 | ||
| Low | 0.48 | 0.58 | 0.69 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 53.4% | 14.3% | ||
| Avg | - | 36.1% | 8.0% | ||
| Low | - | 15.7% | 0.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.